Increasing Treatment Adherence in Co-Occurring Psychiatric and Drug Use Disorders

Phase 2

Completed

• Conditions: Psychiatric Diagnosis; Diagnosis, Dual (Psychiatry); Drug Use Disorders

• Registration Number: NCT00237822
• Lead Sponsor: Yale University

Brief Summary

The investigators are proposing a study of treatment adherence in co-occurring psychiatric and drug use disorders (COD). The proposed study uses a 3-cell/condition design, within which 75 adult outpatients with co-occurring psychiatric disorders and drug abuse/dependence (CODDA) will be randomly assigned to one of the following brief, 8-week, manual-guided interventions following a 2-week "Assessment Only" baseline period:

1. Adherence Feedback (AF); this condition will entail weekly, 20-25 minute sessions of AF, which is a procedure that represents a technological advancement developed by Cramer et al. (1989, 1995, and 1999) and is based on the use of adherence data from the microelectronic monitor in Medication Event Monitoring System (MEMS) caps,

2. AF + Contingency Management (AF + CM); in this condition, participants will receive AF, as described above, PLUS contingency management. CM is based on the behavioral learning theory, which suggests that the occurrence of a behavior is increased as a function of the rate at which it is positively reinforced or rewarded, or

3. AF + Motivational Enhancement Therapy (AF + MET); in this condition, patients will receive AF, as described above, PLUS motivational enhancement therapy. MET is based on the idea that an effective way to motivate behavior change is to assist patients in clarifying their ambivalence (i.e., reasons for and against changing/adhering), utilizing a series of strategies based on client-centered psychotherapy, self-efficacy theory, and social psychology.

The study will allow the evaluation of three hypotheses:

1. AF + MET is superior to AF + CM,

2. AF + MET is superior to AF alone, and

3. AF + CM is superior to AF alone.

Primary outcome measures are:

1. rates of adherence to medication (i.e., selective serotonin reuptake inhibitors or SSRIs), as measured by MEMS caps and self-report,

2. rates of counseling attendance, and

3. reductions in illicit drug use, including achievement of abstinence, as assessed by twice-weekly urine toxicology tests and self-report.

Secondary outcomes include reductions in psychiatric symptomatology and rates of re-hospitalization. The investigators will also evaluate the relationship between adherence and primary and secondary outcomes.

Detailed Description

Not available

Study Timeline

• Study Start: 2003-09
• Status Verified: 2005-10
• Study First Submitted: 2005-10-07
• Study First Submitted QC: 2005-10-07
• Study First Posted: 2005-10-12
• Study Completion: 2007-12
• Last Update Submitted: 2017-10-13
• Last Update Posted: 2017-10-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 75

Inclusion Criteria

• Currently being treated with any class of psychotropic medication
• Have used illicit drugs or abused prescription drugs within the past year
• Are not adhering completely to their medication

Exclusion Criteria

• Current major depressive episode
• Active suicidal/homicidal ideation/intent
• Current manic episode
• Visiting nurse or living in a facility that distributed medications

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Treatment adherence

Secondary Outcome Measures

Name	Time	Method
Drug use
Depression

Trial Locations

Locations (1)

Yale University Substance Abuse Center; 🇺🇸 New Haven, Connecticut, United States